title: How should the potency of HIV vaccine candidates be determined?
authors.affiliation: Div. of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA, 1401 Rockville Pike, HFM-475, Rockville, MD 20852, USA. sheets@cber.fda.gov
authors.forename: R
authors.initials: R
authors.lastname: Sheets
authors.forename: P
authors.initials: P
authors.lastname: Bean
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000914:Antibodies, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D006801:Humans; D009092:Mucous Membrane / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral